Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stephanie Jordaens"'
Autor:
Stephanie Jordaens, Eline Oeyen, Hanny Willems, Filip Ameye, Stefan De Wachter, Patrick Pauwels, Inge Mertens
Publikováno v:
Biomolecules, Vol 13, Iss 6, p 932 (2023)
Urinary extracellular vesicles (EVs) are an attractive source of bladder cancer biomarkers. Here, a protein biomarker discovery study was performed on the protein content of small urinary EVs (sEVs) to identify possible biomarkers for the primary dia
Externí odkaz:
https://doaj.org/article/631d28e18fbf4f199c143ede10167439
Autor:
Stephanie Jordaens, Karen Zwaenepoel, Wiebren Tjalma, Christophe Deben, Koen Beyers, Vanessa Vankerckhoven, Patrick Pauwels, Alex Vorsters
Publikováno v:
International journal of cancer
The aim of this review was to explore the status of urine sampling as a liquid biopsy for noninvasive cancer research by reviewing used preanalytical parameters and protocols. We searched two main health sciences databases, PubMed and Web of Science.
Autor:
Vankerckhoven, Stephanie Jordaens, Amit Arora, Kyle W. MacDonald, Cameron Wood, Jhana O. Hendrickx, Karen Zwaenepoel, Christophe Deben, Wiebren Tjalma, Patrick Pauwels, Koen Beyers, Vanessa
Publikováno v:
Cancers; Volume 15; Issue 12; Pages: 3119
Liquid biopsy is a revolutionary tool that is gaining momentum in the field of cancer research. As a body fluid, urine can be used in non-invasive diagnostics for various types of cancer. We investigated the performance of UAS™ as a preservative fo
Autor:
Mertens, Stephanie Jordaens, Eline Oeyen, Hanny Willems, Filip Ameye, Stefan De Wachter, Patrick Pauwels, Inge
Publikováno v:
Biomolecules; Volume 13; Issue 6; Pages: 932
Urinary extracellular vesicles (EVs) are an attractive source of bladder cancer biomarkers. Here, a protein biomarker discovery study was performed on the protein content of small urinary EVs (sEVs) to identify possible biomarkers for the primary dia
Autor:
Leah Cooksey, Stephanie Jordaens, Laurie Freire Boullosa, Kim Orchard, Ken I. Mills, Viggo Van Tendeloo, Evelien Smits, Barbara-Ann Guinn
Publikováno v:
Cancer Immunology, Immunotherapy
Cancer immunology and immunotherapy
Cancer immunology and immunotherapy
Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lymphoblasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the associat
Autor:
Barbara-Ann Guinn, Ken I. Mills, Laurence Orchard, Stephanie Bonney, Viggo Van Tendeloo, Kim Orchard, Leah Cooksey, Matthew Coutinho, Stephanie Jordaens
Publikováno v:
Jordaens, S, Cooksey, L, Bonney, S, Orchard, L, Coutinho, M, Van Tendeloo, V, Mills, K I, Orchard, K & Guinn, B-A 2020, ' Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia ', British Journal of Haematology, vol. 189, no. 3, pp. 500-512 . https://doi.org/10.1111/bjh.16407
British journal of haematology
British journal of haematology
Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80% of cases occur in children where ALL is well understood and treated. However it has a devastating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8fe1442d05a82455e5ad9d9ba9bf17b
https://pure.qub.ac.uk/en/publications/serum-profiling-identifies-ibrutinib-as-a-treatment-option-for-young-adults-with-bcell-acute-lymphoblastic-leukaemia(d7fa9a66-a865-453b-a5ee-211e923e3daf).html
https://pure.qub.ac.uk/en/publications/serum-profiling-identifies-ibrutinib-as-a-treatment-option-for-young-adults-with-bcell-acute-lymphoblastic-leukaemia(d7fa9a66-a865-453b-a5ee-211e923e3daf).html
Autor:
Karen Zwaenepoel, Jo Raskin, Stephanie Jordaens, Geert Baggerman, Laure Sorber, Vasiliki Siozopoulou, Marc Peeters, Geert Roeyen, Elien Augustus, Patrick Pauwels
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1675, p 1675 (2021)
Cancers, Vol 13, Iss 1675, p 1675 (2021)
Simple Summary The introduction of immunotherapy modified the cancer treatment landscape, especially for non-small cell lung cancer (NSCLC). Unfortunately, only a subgroup of patients benefits from this therapy. Currently, the only validated companio